

DATE: February 5, 2004

SHEET 1_ of 1_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

7283.US.01

SERIAL NO.

Not assigned yet

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)

T. Kolasa, et al.

FILING DATE

February 5, 2004

GROUP

Not assigned yet

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRAN- SLATION
							YES NO
EB	B1	1,384,523 ✓	02/19/75	Great Britain			
EB	B2	1,378,080	12/18/74	Great Britain			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

EB	C1 ✓	Andersson, K. et al., "Physiology of penile erection," <i>Physiol. Rev.</i> 75:191-236 (1995)
	C2 ✓	Hrib, N., "The dopamine D4 receptor: a controversial therapeutic target", <i>Drugs of the Future</i> : 25:587-611 (2000)
	C3 ✓	DeGroat, W. et al., "Neural Control of Penile Erection, in : Nervous control of urogenital system," <i>Hardwood Academic Publishers, Chur, Switzerland, Vol. 3 (ed. Maggi, C.):467-524 (1993)</i>
	C4 ✓	Dula, E. et al., "Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction," <i>Urology</i> 56:130-135 (2000)
	C5 ✓	Milligan, G. et al., "Chimaeric G proteins: their potential use in drug discovery," <i>Trends Pharmacol Sci</i> 20:118-124 (1998)
	C6 ✓	Missale, C. et al. "Dopamine receptors: from structure to function," <i>Physiol Rev</i> 78:189-225 (1998)
	C7 ✓	Morales, A. et al., "Oral and Topical Treatment of Erectile Dysfunction: present and future," <i>Urologic Clinics of North America</i> , vol. 22:879-886 (1995)
	C8 ✓	Moreland, RB, et al., "Prospectives for Pharmacotherapy of Male Erectile Dysfunction," <i>Curr Opinion CPNS Invest Drugs</i> , 2:283-302 (2000)
	C9 ✓	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," <i>Urology</i> 161:214 (abstract 821) (1999)
	C10 ✓	Primus, R. et al., "Localization and characterization of dopamine D ₄ binding sites in rat and human brain by use of the novel D ₄ receptor-selective ligand [³ H]NGD 94-1," <i>J. Pharmacol Exp. Ther</i> 282:1020-1027 (1997)
	C11 ✓	Melis M., et al., "Dopamine and sexual behavior", <i>Neuroscience and Behavioral Reviews</i> 19: 19-38 (1995)
	C12 ✓	Suzuki, M. et al., "D ₃ dopamine receptor mRNA is widely express in human brain," <i>Brian Res</i> 779:58-74 (1998)
	C13 ✓	Vallone, D. et al., "Structure and function of dopamine receptors," <i>Neurosci Biobehav. Rev.</i> 24:125-132 (2000)
	C14 ✓	Chen F., et al., "Effects of dopamine, apomorphine, gamma hydroxybutiric acid, haloperidol, and pimozide on reflex bradycardia in rats", <i>J. Pharmacol. Exp. Therap.</i> 214:427-432 (1980)
	C15 ✓	Hahn R.A. et al., "Primate cardiovascular responses mediated by dopaminergic receptors: effects of N,N-dihydrodopamine and LY171555" <i>J. Pharmacol Exp. Therap.</i> 229:132-138 (1984)
	C16 ✓	Bendele et al., "Anti-inflammatory activity of pergolide, a dopamine receptor agonist", <i>J. Pharmacol Exp. Therap.</i> 259:169-175 (1991)
	C17 ✓	Lissoni et al., "Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer-related hyperprolactinemia", <i>Neuroendocrinology Letters</i> 21:405-408 (2000)
	C18 ✓	Martinez-Esparza et al., "New 1-Aryl-3-(4-aryl piperazin-1-yl)propane derivatives with dual action at 5-HT _{1A} Serotonin Receptors and Serotonin transporter, as a new class of antidepressant" <i>J. Med. Chem.</i> 44:418-428 (2001)

EXAMINER

E Bernhard

DATE CONSIDERED

4/15/06

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)